Pre-order Enquiry
Request Free Sample
Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Report 2020
SKU ID : QYR-16691132 | Publishing Date : 27-Oct-2020 | No. of pages : 131
Request Sample
Request Customization
Check Discounts
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.
Market Analysis and Insights: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market
The global Glucagon Like Peptide-1 (GLP-1) Agonists market size is projected to reach US$ 16460 million by 2026, from US$ 7781.9 million in 2020, at a CAGR of 13.3% during 2021-2026.
Global Glucagon Like Peptide-1 (GLP-1) Agonists Scope and Market Size
The global Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Glucagon Like Peptide-1 (GLP-1) Agonists market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented into
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segment by Application, the Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented into
Hospital
Pharmacy
Other
The Glucagon Like Peptide-1 (GLP-1) Agonists market is analysed and market size information is provided by regions (countries). Segment by Application, the Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Glucagon Like Peptide-1 (GLP-1) Agonists market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Glucagon Like Peptide-1 (GLP-1) Agonists business, the date to enter into the Glucagon Like Peptide-1 (GLP-1) Agonists market, Glucagon Like Peptide-1 (GLP-1) Agonists product introduction, recent developments, etc.
The major vendors covered:
Novo Nordisk
AstraZeneca
Eli Lilly
GSK
Sanofi
Bristol-Myers Squibb
Amylin
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.
Market Analysis and Insights: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market
The global Glucagon Like Peptide-1 (GLP-1) Agonists market size is projected to reach US$ 16460 million by 2026, from US$ 7781.9 million in 2020, at a CAGR of 13.3% during 2021-2026.
Global Glucagon Like Peptide-1 (GLP-1) Agonists Scope and Market Size
The global Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Glucagon Like Peptide-1 (GLP-1) Agonists market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented into
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segment by Application, the Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented into
Hospital
Pharmacy
Other
The Glucagon Like Peptide-1 (GLP-1) Agonists market is analysed and market size information is provided by regions (countries). Segment by Application, the Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape
and Glucagon Like Peptide-1 (GLP-1) Agonists Market Share AnalysisGlucagon Like Peptide-1 (GLP-1) Agonists market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Glucagon Like Peptide-1 (GLP-1) Agonists business, the date to enter into the Glucagon Like Peptide-1 (GLP-1) Agonists market, Glucagon Like Peptide-1 (GLP-1) Agonists product introduction, recent developments, etc.
The major vendors covered:
Novo Nordisk
AstraZeneca
Eli Lilly
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
